Literatura científica selecionada sobre o tema "HIV/Hepatitis C"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "HIV/Hepatitis C".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "HIV/Hepatitis C"
Crobu, Maria Grazia, Paolo Ravanini, Clotilde Impaloni, Claudia Martello, Olivia Bargiacchi, Christian Di Domenico, Giulia Faolotto et al. "Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection". Viruses 16, n.º 6 (20 de junho de 2024): 992. http://dx.doi.org/10.3390/v16060992.
Texto completo da fonteDickson-Spillmann, Maria, Severin Haug, Ambros Uchtenhagen, Philip Bruggmann e Michael P. Schaub. "Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C Infection". European Addiction Research 22, n.º 4 (11 de dezembro de 2015): 181–91. http://dx.doi.org/10.1159/000441973.
Texto completo da fonteShrestha, Lok Bahadur, Gopal K. Yadav, Saugat Pradhan, Abhilasha Sharma, Tejendra Pandit, Roshan Chhetry e Basudha Khanal. "Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal". PLOS ONE 17, n.º 3 (3 de março de 2022): e0264791. http://dx.doi.org/10.1371/journal.pone.0264791.
Texto completo da fonteSattarova, Gulsunai. "PREVALENCE AND GENOTYPES OF HEPATITIS B AND C VIRUS AMONG HIV-INFECTED PEOPLE". Alatoo Academic Studies 23, n.º 3 (30 de setembro de 2023): 497–506. http://dx.doi.org/10.17015/aas.2023.233.50.
Texto completo da fonteTserashkou, D. V., V. M. Mitsura, E. V. Voropaev e O. V. Osipkina. "VIRAL COINFECTIONS IN PATIENTS WITH CHRONIC HEPATITIS B: THEIR PREVALENCE AND CLINICAL SIGNIFICANCE". Hepatology and Gastroenterology 4, n.º 2 (2020): 171–76. http://dx.doi.org/10.25298/2616-5546-2020-4-2-171-176.
Texto completo da fonteSuman, Sonu. "Clinical, haematological, and biochemical profile of HIV patient co-infected with hepatitis B and /or C". International Journal of Research in Medical Sciences 8, n.º 11 (28 de outubro de 2020): 3955. http://dx.doi.org/10.18203/2320-6012.ijrms20204885.
Texto completo da fonteSeyoum, Eleni, Meaza Demissie, Alemayehu Worku, Andargachew Mulu, Alemseged Abdissa e Yemane Berhane. "HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study". PLOS ONE 17, n.º 4 (22 de abril de 2022): e0267230. http://dx.doi.org/10.1371/journal.pone.0267230.
Texto completo da fonteRiddhi Pradhan, Kirti Hemwani, Vidit Khandelwal, Bamboriya BL, Yogyata Marothi e Varsha Saxena. "A cross-sectional study on co-infection of hepatitis B and hepatitis C among people living with HIV/AIDS from a tertiary care hospital of Central India". Asian Journal of Medical Sciences 14, n.º 4 (1 de abril de 2023): 61–67. http://dx.doi.org/10.3126/ajms.v14i4.50299.
Texto completo da fonteGuo, Fuying, e Lingzhou Yang. "Research Progress on HIV/AIDS with Concomitant Hepatitis B Virus and/or Hepatitis C Virus Infection". Infection International 4, n.º 1 (1 de março de 2015): 16–20. http://dx.doi.org/10.1515/ii-2017-0099.
Texto completo da fonteBasimane-Bisimwa, Parvine, Giscard Wilfried Koyaweda, Edgarthe Ngaïganam, Ulrich Vickos, Ornella Anne Demi Sibiro, Brice Martial Yambiyo, Benjamin Seydou Sombié et al. "Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic". PLOS ONE 19, n.º 5 (9 de maio de 2024): e0291155. http://dx.doi.org/10.1371/journal.pone.0291155.
Texto completo da fonteTeses / dissertações sobre o assunto "HIV/Hepatitis C"
Mohsen, Abdul Hadi. "The epidemiology of hepatitis C and HCV-HIV coinfection". Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424448.
Texto completo da fonteFalconer, Karolin. "HIV-1/HCV co-infection immunity and viral dynamics /". Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-762-7/.
Texto completo da fonteYuen, King-tai, e 袁敬弟. "A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193555.
Texto completo da fontepublished_or_final_version
Medical Sciences
Master
Master of Medical Sciences
Fialho, Renata. "Neuropsychiatric manifestations of hepatitis C treatment in HIV/HCV co-infection". Thesis, University of Sussex, 2017. http://sro.sussex.ac.uk/id/eprint/71260/.
Texto completo da fonteBertol, Bruna Cristina. "Expressão da molécula HLA-G e polimorfismos da região codificadora do gene HLA-G em pacientes infectados pelo vírus da hepatite C (HCV) apresentando ou não a coinfecção pelo vírus da imunodeficiência humana (HIV)". Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/17/17147/tde-10012017-112046/.
Texto completo da fonteHepatitis C, caused by the hepatitis C virus (HCV), affects millions of people worldwide. The transmission of HCV is similar to HIV, which explains the high prevalence of coinfection. HCV-HIV coinfected patients have higher rate of liver fibrosis progression and mortality when compared to HCV monoinfected patients. Thus, the study of genes and/or molecules that control the immune response is relevant. In the present study, we evaluated the role of human leukocyte antigen G (HLA-G), a molecule known by its immunomodulatory activity, which is capable to inhibit T cell activation and cytotoxic activity of natural killer (NK) cells and CD8+ T cells, in addition to inducing the formation of regulatory T cells. We studied 216 HCV patients, 135 HIV-HCV coinfected patients and 152 uninfected individual. The variability of the HLA-G gene was evaluated by Sanger sequencing and the hepatic expression of the molecule by immunohistochemistry. The HLA-G expression was observed only in liver tissue of patients, mainly in hepatocytes. The increased HLA-G expression was associated with increased liver fibrosis and necroinflammatory activity in both groups of patients. The age greater than or equal to 40 years and the non-white skin color were also associated with increased hepatic expression of the molecule in the HCV patients. Other host factors analyzed as gender and HCV genotype were not associated with the level of HLA-G expression in the liver. The frequency of HLA-G*01:01:01:01 allele was increased in HCV patients and G*01:05N decreased in HCV-HIV coinfected patients, however, there was no significant association between the genetic variability of HLA-G and HLA-G liver expression. The present study contributes to expand the knowledge regarding the participation of HLA-G in chronic C hepatitis, associated or not with the HIV infection.
Souza, Rafael Leme Cardoso. "Avaliação tecnológica do teste molecular (NAT) para HIV, HCV e HBV na triagem de sangue no Brasil". Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/99/99131/tde-09102018-090250/.
Texto completo da fonteAfter years of discussion, nucleic acid (NAT) testing in the blood screening for HIV and HCV was implemented in Brazil in 2013 and HBV in 2016. One of the reasons cited for the delay in its implementation was the high cost that would be added to serology screening and a comprehensive economic assessment of its efficiency in the country is not yet available. Several articles have already shown that the incremental cost-utility ratio (ICUR) of NAT versus serology ranges from 0.21 to 8.84 million American dollars (US$) for each QALY gained. This large variation is mainly due to differences between the mean age of the blood recipient, viruses\' incidence / prevalence among donor population, cost of medical tests and treatments, HBV vaccine coverage, and sensitivity of the test used. Thus, a comprehensive evaluation of this technology and its effectiveness under the perspective of the Brazilian public health system (SUS) is needed. Objectives: Development of a systematic review (RevS) of complete economic studies about the use of NAT for HIV, HCV and / or HBV in the world. Conduct an economic evaluation of NAT under SUS perspective; characterize Brazilian blood donations in the serology \"window period\". Methods: Cochrane RevS Methodology of the Medline, Embase, LILACS, CRD, CRD ECO, Google Scholar and IDEAS databases; Questionnaire applied to blood banks and online economic model from the International Society of Blood Transfusion (ISBT) to calculate the ICUR for \"NAT in mini-pool of six individual samples\" (MP6) versus \"Serology Tests\" (SR) in Brazil. Results: Fourteen studies from sixteen different countries were assessed. NAT was most relevant in low-income countries, where there are the highest prevalences and viral incidences, lower rates of repeat donors and younger recipients of blood (RS). Most of the studies concluded that NAT, regardless of the virus evaluated, is not cost-effective. Differences in the characteristics of the studies were related to the costs and age of RS. The major deviations from RevS standards were: not including the rationale for selecting the outcomes and the model used and not being clear about the authors\' conflict of interest; MP6 vs SR showed an ICUR of US$ 231.630,00/QALY, 26,2 times Brazilian GND per capita) and an ICER of US$ 330.790,00/Life year gained (AVG). The univariate sensitivity analysis of the model demonstrated that only changes on discount rate, NAT cost, RS age and viruses\' epidemiology significantly altered the ICUR in a range between US$ 76.957,00/QALY and US$ 933.311,00/QALY; Most RS window period cases in Brazil are young, average of 29 years old, male, with at least high school education completed and even with the requirement of Anti-HBc in Brazil, NAT-HBV is the one that presented the highest yield. Conclusions: Young people, mainly, still seek blood banks as testing sites, especially after a risk behavior. It is extremely important to reveal the real and complete cost of the Brazilian NAT to fully evaluate its efficiency and, if needed, reassess its current reimbursement model, allowing the wellbeing defense of the population and public interest.
Del-Rios, Nativa Helena Alves. "Estudo epidemiológico e molecular da infecção pelo vírus da Hepatite C em indivíduos infectados pelo vírus da Imunodeficiência Humana em Goiânia-Goiás". Universidade Federal de Goiás, 2011. http://repositorio.bc.ufg.br/tede/handle/tede/7241.
Texto completo da fonteRejected by Erika Demachki (erikademachki@gmail.com), reason: on 2017-04-27T18:05:52Z (GMT)
Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-04-27T18:06:12Z No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-05-03T11:47:33Z (GMT) No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Made available in DSpace on 2017-05-03T11:47:33Z (GMT). No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2011-03-30
Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG
The hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are characterized by causing chronic infections in the host. The advent of potent antiretroviral therapy has resulted in a significant reduction in the incidence of opportunist infections, and thus greater life expectancy for HIV positive patients. However, the liver disease appears as a major cause of morbidity and mortality among these patients, especially those related to hepatitis C virus. Co-infection with HCV/HIV induces a worse prognosis for both infections, which may lead to the development of AIDS, a faster rapid evolution to chronic active hepatitis and / or liver cirrhosis and death. This study aimed to investigate the epidemiology and molecular profile HCV infection in HIV-infected individuals with no prior antiretroviral therapy, seen in the referral hospital for the treatment of infectious diseases (Hospital for Tropical Diseases - Anuar Auad / HDT) in Goiania, Goiás. A total of 505 treatment naïve individuals and were referred to the HDT, from April 2009 to April 2010 were interviewed and underwent blood collection. All sera were tested for antibodies to HCV (anti-HCV) and for HCV RNA by polymerase chain reaction (PCR). Genotyping was performed by reverse hybridization by the Line Probe Assay (LiPA) method. The prevalence of anti-HCV was 4.6% (95% CI: 3.0 to 6.8). The viral RNA was detected in 65.2% (15/23) of anti-HCV positive samples. The genotypes identified were 1 (subtypes 1a and 1b) and 3 (subtype 3a). The age > 40 years, living in other states or Goiania city, surgery, injecting and non-injecting drug and anti-HBc positive (antibody to core antigen of hepatitis B virus) were associated with HCV infection after logistic regression. The data presented shows the vulnerability of the HIV sropositive population to acquisition of infectious diseases such as HCV infection. Thus, the information obtained will be essential for planning public health interventions, preventing and control of hepatitis C in this population.
Os vírus da hepatite C (HCV) e da imunodeficiência humana (HIV) causam infecções crônicas no hospedeiro. O advento da terapia antiretroviral potente trouxe uma redução da incidência de infecções oportunistas, e consequentemente, uma maior expectativa de vida aos pacientes HIV soropositivos. No entanto, as hepatopatias surgem como uma das principais causas de morbimortalidade entre esses pacientes, principalmente aquelas relacionadas ao vírus C. A coinfecção HCV/HIV induz a um pior prognóstico de ambas as infecções, podendo levar ao desenvolvimento da Aids, evolução mais rápida para hepatite crônica ativa e/ou cirrose hepática e morte. Este estudo teve como objetivo investigar o perfil epidemiológico e molecular da infecção pelo HCV em indivíduos infectados pelo HIV, sem tratamento antiretroviral prévio, atendidos no Hospital de referência para o tratamento de doenças infecciosas (Hospital de Doenças Tropicais - Anuar Auad / HDT) em Goiânia, Goiás. Um total de 505 indivíduos, virgens de tratamento, encaminhados ao HDT, no período de abril/2009 a abril/2010, foram entrevistados e submetidos à coleta de sangue. As amostras (soros) foram testadas para a detecção de anticorpos para o HCV (ELISA/LIA) e submetidas à identificação do RNA-HCV pela reação em cadeia da polimerase (PCR). A genotipagem foi realizada por hibridização reversa, pelo método Line Probe Assay (LiPA). A prevalência para anti-HCV foi de 4,6% (IC 95%: 3,0-6,8). O RNA viral foi detectado em 15 amostras, sendo todas elas anti-HCV positivas. Foram identificados os genótipos 1 e 3, com predomínio do subtipo 1a, seguido dos subtipos 1b e 3a. As variáveis idade superior a 40 anos, ser procedente de Goiânia ou outros estados, cirurgia, uso de drogas injetáveis e não-injetáveis, história de prisão e positividade ao anti-HBc foram associados à infecção pelo vírus da hepatite C, após regressão logística. Os dados apresentados revelam a vulnerabilidade da população HIV soropositiva à aquisição de doenças infecciosas como a infecção pelo HCV. Assim, as informações obtidas serão essenciais para o planejamento de ações de saúde pública para a prevenção e controle da hepatite C nessa população.
Gröner, Jan Benedikt. "Mitochondriale Dysfunktion bei chronischer Hepatitis B, chronischer Hepatitis C und bei HIV-Postexpositionsprophylaxe". Diss., lmu, 2011. http://nbn-resolving.de/urn:nbn:de:bvb:19-135665.
Texto completo da fonteBarbosa, Alexandre Naime [UNESP]. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C". Universidade Estadual Paulista (UNESP), 2010. http://hdl.handle.net/11449/101466.
Texto completo da fonteCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Universidade Estadual Paulista (UNESP)
A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico...
Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)
Barbosa, Alexandre Naime. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C /". Botucatu : [s.n.], 2010. http://hdl.handle.net/11449/101466.
Texto completo da fonteBanca: Alexandrina Sartori
Banca: Ricardo Sobhie Diaz
Banca: Fernando Lopes Gonçalves Júnior
Resumo: A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)
Doutor
Livros sobre o assunto "HIV/Hepatitis C"
Ireland. Hepatitis C Compensation Tribunal. Annual report of the Hepatitis C Compensation Tribunal. Dublin: Stationery Office, 2003.
Encontre o texto completo da fonteSaskatchewan Subcommittee on HIV/AIDS. Guidelines for the management of potential exposures to Hepatitis B, Hepatitis C, HIV, and recommendations for post-exposure prophyalxis. Saskatchewan: Saskatchewan Health, 2004.
Encontre o texto completo da fonteDublin, Ireland. Minister for Justice, Equality, and Law Reform. e Trinity College (Dublin, Ireland). Dept. of Community Health and General Practice., eds. Hepatitis B, hepatitis C and HIV in Irish prisoners: Prevalence and risk. Dublin: Stationery Office, 1999.
Encontre o texto completo da fonteMusharraf, Husain, e Population Council (Bangladesh), eds. Prevalence of HIV, HBV, HCV and syphilis markers in pregnant women of Bangladesh. Dhaka, Bangladesh: Population Council, 1997.
Encontre o texto completo da fonteSan Francisco (Calif.). Dept. of Public Health. Communicable Disease Control Unit. Registry match: Chronic hepatitis B, hepatitis C infection and HIV : 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2011.
Encontre o texto completo da fonteAssociation, American Nurses. HIV, Hepatitis-B, Hepatitis-C: Blood-borne diseases; nurses' risks, rights, and responsibilities. Washington, DC: ANA, 1993.
Encontre o texto completo da fonteDias, Giselle. Hard time: HIV and hepatitis C prevention programming for prisoners in Canada. Toronto: Canadian HIV/AIDS Legal Network = Râeseau juridique canadien VIH/Sida, 2007.
Encontre o texto completo da fonteThiemann, Lillian. Double jeopardy: The HIV/HCV co-infection handbook. New York: Community Prescription Service, 1999.
Encontre o texto completo da fonteRuiz, Juan D. Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California correctional system. [Sacramento]: California Dept. of Health Services, Office of Aids, HIV/AIDS Epidemiology Branch, 1996.
Encontre o texto completo da fonteTribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Dublin: Stationery Office, 2002.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "HIV/Hepatitis C"
Salmon-Ceron, Dominique, J. E. Arends, C. Leoni, C. Solas e G. Peytavin. "HIV/HCV Coinfection: Current Challenges". In Viral Hepatitis: Chronic Hepatitis C, 141–57. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_7.
Texto completo da fonteIngiliz, Patrick, Maud Lemoine e Yves Benhamou. "Chronic HCV and HIV Coinfection". In Chronic Hepatitis C Virus, 75–91. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_7.
Texto completo da fonteSulkowski, Mark S. "Hepatitis C: Natural History". In HIV and Liver Disease, 101–5. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1712-6_11.
Texto completo da fonteMatthews, Gail V., e Gregory J. Dore. "HIV and Hepatitis C Co-Infection". In Advanced Therapy for Hepatitis C, 177–84. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444346343.ch22.
Texto completo da fonteChung, Raymond, e Gyanprakash Avinash Ketwaroo. "Hepatitis C Virus Treatment in HIV". In HIV and Liver Disease, 133–39. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1712-6_15.
Texto completo da fonteCarlin, Joseph, Maria Cassia Mendes-Correa e Marina Núñez. "Hepatitis B and C". In Sexually Transmitted Infections in HIV-Infected Adults and Special Populations, 175–89. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56694-8_10.
Texto completo da fonteRauch, Andri, e Jürgen Kurt Rockstroh. "Hepatitis C Virus Infection and HIV". In Encyclopedia of AIDS, 1–9. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-9610-6_426-1.
Texto completo da fontePandya, Shuchi, Misbahuddin Syed, Manuel Castro, Jamie P. Morano e Beata Casanas. "Hepatitis C and HIV Neurological Implications". In Global Virology II - HIV and NeuroAIDS, 625–43. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7290-6_24.
Texto completo da fonteRauch, Andri, e Jürgen Kurt Rockstroh. "Hepatitis C Virus Infection and HIV". In Encyclopedia of AIDS, 625–33. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7101-5_426.
Texto completo da fontePresterl, Elisabeth, Magda Diab-El Schahawi, Luigi Segagni Lusignani, Helga Paula e Jacqui S. Reilly. "Blood-Borne Viruses: HIV, Hepatitis B, and Hepatitis C". In Basic Microbiology and Infection Control for Midwives, 143–49. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02026-2_15.
Texto completo da fonteTrabalhos de conferências sobre o assunto "HIV/Hepatitis C"
Paschoini, MC, LN Resende, MM Mendonça, GPM Gomide e JU Ribeiro. "P3.181 Hepatitis c: challenging modern obstetrics". In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.416.
Texto completo da fonteSchmidt, Axel. "S03.4 Hepatitis C in HIV-negative MSM – a growing concern?" In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.27.
Texto completo da fonteBrieva Herrero, MT, I. Reyes Torres, M. Sáez-Torres de Vicente, P. López López, M. Frias Casas e A. Rivero Juárez. "4CPS-267 Lack of hepatitis C virus uptake in HIV/HCV co-infected patients". In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.416.
Texto completo da fonteSantos, Alaides de Abreu, Talia Hahn Augusto, Geovane Barbosa da Silva, Tatiana Mugnol, Luiza Mariana Alvarez Elicker, Taila Brant, Ana Lidia Toebe, Kelly Silva Rodrigues, Janaina Coser e Janice de Fátima Pavan Zanella. "Vírus da hepatite C em pacientes hemodialisados: uma breve revisão". In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p250.
Texto completo da fonteMckee, Geoff, Nuria Chapinal, Zahid Butt, Carmine Rossi, Stanley Wong, Mark Gilbert, Jason Wong et al. "P388 Evolution of hepatitis C care cascades among HIV and hepatitis B co-infected patients in british columbia, canada". In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.483.
Texto completo da fonteRey, MB Contreras, J. Estaire Gutiérrez, R. Sánchez del Moral, MM Romero Alonso, MA Bolivar Raya e C. Bocanegra Martín. "5PSQ-046 Direct-acting antivirals for hepatitis c virus in hiv co-infected patients". In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.400.
Texto completo da fontePrasad, Yash, Khine Phyu, Lee Parker, Mark Aldersley e Emma Page. "P63 ‘Get tested LeEDs’: testing for hepatitis B, hepatitis C and HIV in an Urban emergency department via notional consent". In BASL Abstracts, 21–23 September, 2020. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-basl.73.
Texto completo da fonteRonchi, Bruna Ribas, Gabriela Marçal Rios, Rosalie Kupka Knoll e Carolina Cardoso. "P3.29 Prevalence of hiv, sifilis, hepatitis b and hepatitis c in the inmates of the penitentiary complex of vale do itajaÍ-sc". In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.266.
Texto completo da fonteKerschberger, B., N. Ntshalintshali, M. Mafomisa, E. Mabhena, M. Daka, E. Mukooza, SV Dlamini et al. "High burden of sexually transmitted infections and poor diagnostic performance of syndromic approaches within a decentralised HIV care setting in Eswatini". In MSF Scientific Day International 2023. NYC: MSF-USA, 2023. http://dx.doi.org/10.57740/4e0e-e138.
Texto completo da fonteSow, P. "P432 The prevalence of co-infection with HIV, Hepatitis C and TB among patients infected by HIV/AIDS in Senegal". In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.452.
Texto completo da fonteRelatórios de organizações sobre o assunto "HIV/Hepatitis C"
Goller, Jane, Stephanie Munari, Cassandra Caddy, Teralynn Ludwick, Jacqueline Coombe, Meredith Temple-Smith, Lena Sanci e Jane Hocking. General Practice engagement: STI, HIV and viral hepatitis care. The Sax Institute, junho de 2023. http://dx.doi.org/10.57022/lnur4773.
Texto completo da fonteBuresh, Christopher. The Opioid Epidemic in Iowa and the Connection to Hepatitis C and HIV Outbreaks. Iowa City, Iowa: University of Iowa Public Policy Center, janeiro de 2019. http://dx.doi.org/10.17077/rep.001111.
Texto completo da fonteGoldstein, Neal. Epidemiology Blog of Neal D. Goldstein, PhD, MBI. Neal D. Goldstein, 2023. http://dx.doi.org/10.17918/goldsteinepi.
Texto completo da fonteSaraswati, Lopamudra, Mary Sebastian, Avina Sarna, Vartika Sharma, Ira Madan, Dean Lewis, Ibou Thior e Waimar Tun. Prevalence of HIV, hepatitis B and C, and co-infection in a cohort of male injection drug users in Delhi. Population Council, 2013. http://dx.doi.org/10.31899/hiv10.1001.
Texto completo da fonteMark, Tami L., William N. Dowd e Carol L. Council. Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality. RTI Press, julho de 2020. http://dx.doi.org/10.3768/rtipress.2020.rr.0040.2007.
Texto completo da fonte